Your browser doesn't support javascript.
loading
Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals.
Eybpoosh, Sana; Biglari, Alireza; Sorouri, Rahim; Ashrafian, Fatemeh; Sadat Larijani, Mona; Verez-Bencomo, Vicente; Toledo-Romani, Maria Eugenia; Valenzuela Silva, Carmen; Salehi-Vaziri, Mostafa; Dahmardeh, Sarah; Doroud, Delaram; Banifazl, Mohammad; Mostafavi, Ehsan; Bavand, Anahita; Ramezani, Amitis.
Afiliación
  • Eybpoosh S; Department of Epidemiology and Biostatistics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran.
  • Biglari A; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Sorouri R; IPI Directorate, Pasteur Institute of Iran, Tehran, Iran.
  • Ashrafian F; Department of Microbiology, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran.
  • Sadat Larijani M; Clinical Research Department, Pasteur Institute of Iran, Tehran, Iran.
  • Verez-Bencomo V; Clinical Research Department, Pasteur Institute of Iran, Tehran, Iran.
  • Toledo-Romani ME; Finlay Vaccine Institute, Havana, Cuba.
  • Valenzuela Silva C; Pedro Kourí Tropical Medicine Institute, Havana, Cuba.
  • Salehi-Vaziri M; Cybernetics, Mathematics and Physics Institute, Havana, Cuba.
  • Dahmardeh S; COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran.
  • Doroud D; Vaccination Department, Pasteur Institute of Iran, Tehran, Iran.
  • Banifazl M; Quality Control Department, Production and research Complex, Pasteur Institute of Iran, Tehran, Iran.
  • Mostafavi E; Iranian Society for Support of Patients with Infectious Disease, Tehran, Iran.
  • Bavand A; Department of Epidemiology and Biostatistics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran.
  • Ramezani A; Clinical Research Department, Pasteur Institute of Iran, Tehran, Iran.
PLoS Pathog ; 19(11): e1011744, 2023 Nov.
Article en En | MEDLINE | ID: mdl-37910480
BACKGROUND: This study aimed at evaluation and comparison of PastoCovac Plus protein-subunit vaccine in parallel with ChAdOx1-S (AstraZeneca) and BBIBP-CorV (Sinopharm) in primarily vaccinated volunteers with two doses of ChAdOx1-S or BBIBP-CorV. MATERIALS AND METHODS: 194 volunteers enrolled the study who were previously primed with 2 doses of ChAdOx1-S or BBIBP-CorV vaccines. They were divided into two heterologous regimens receiving a third dose of PastoCovac Plus, and two parallel homologous groups receiving the third dose of BBIBP-CorV or ChAdOx1-S. Serum samples were obtained just before and 4 weeks after booster dose. Anti-spike IgG and neutralizing antibodies were quantified and the conventional live-virus neutralization titer, (cVNT50) assay was done against Omicron BA.5 variant. Moreover, the adverse events data were recorded after receiving booster doses. RESULTS: ChAdOx1-S/PastoCovac Plus group reached 73.0 units increase in anti-Spike IgG rise compared to the ChAdOx1-S/ ChAdOx1-S (P: 0.016). No significant difference was observed between the two groups regarding neutralizing antibody rise (P: 0.256), indicating equivalency of both booster types. Adjusting for baseline titers, the BBIBP-CorV/PastoCovac Plus group showed 135.2 units increase (P<0.0001) in anti-Spike IgG, and 3.1 (P: 0.008) unit increase in mean rise of neutralizing antibodies compared to the homologous group. Adjustment for COVID-19 history, age, underlying diseases, and baseline antibody titers increased the odds of anti-Spike IgG fourfold rise both in the ChAdOx1-S (OR: 1.9; P: 0.199) and BBIBP CorV (OR: 37.3; P< 0.0001) heterologous groups compared to their corresponding homologous arms. The odds of neutralizing antibody fourfold rise, after adjustment for the same variables, was 2.4 (P: 0.610) for the ChAdOx1-S heterologous group and 5.4 (P: 0.286) for the BBIBP CorV heterologous groups compared to their corresponding homologous groups. All the booster types had the potency to neutralize BA.5 variant with no significant difference. The highest rate of adverse event incidence was recorded for ChAdOx1-S homologous group. CONCLUSIONS: PastoCovac Plus booster application in primed individuals with BBIBP-CorV or ChAdOx1-S successfully increased specific antibodies' levels without any serious adverse events. This vaccine could be administrated in the heterologous regimen to effectively boost humoral immune responses.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: COVID-19 Límite: Humans Idioma: En Revista: PLoS Pathog Año: 2023 Tipo del documento: Article País de afiliación: Irán

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: COVID-19 Límite: Humans Idioma: En Revista: PLoS Pathog Año: 2023 Tipo del documento: Article País de afiliación: Irán